Greenwich LifeSciences (NASDAQ:GLSI – Get Free Report) announced its quarterly earnings results on Monday. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.06), FiscalAI reports.
Greenwich LifeSciences Price Performance
GLSI stock traded down $1.18 during trading hours on Monday, reaching $13.76. 153,544 shares of the stock were exchanged, compared to its average volume of 204,451. The firm’s 50-day moving average is $16.57 and its 200-day moving average is $21.06. The company has a market cap of $201.97 million, a price-to-earnings ratio of -8.94 and a beta of 1.57. Greenwich LifeSciences has a 12 month low of $7.78 and a 12 month high of $34.10.
Analyst Upgrades and Downgrades
GLSI has been the topic of several research analyst reports. Weiss Ratings downgraded Greenwich LifeSciences from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, October 29th. HC Wainwright boosted their target price on Greenwich LifeSciences from $50.00 to $69.00 and gave the company a “buy” rating in a research note on Tuesday, July 21st. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $69.00.
View Our Latest Stock Report on Greenwich LifeSciences
Greenwich LifeSciences Company Profile
Greenwich LifeSciences, Inc. is a clinical-stage biotechnology company developing immunotherapies intended to reduce the risk of breast cancer recurrence. The company’s work centers on GP2, an investigational peptide-based vaccine designed for patients with HER2/neu-positive breast cancer who have completed standard treatment. GP2 is intended to stimulate an immune response against cancer cells expressing HER2/neu and is administered with the immune-system stimulant GM-CSF. Greenwich LifeSciences is evaluating the candidate in clinical trials; it does not have an approved commercial product.
Featured Stories
- Five stocks we like better than Greenwich LifeSciences
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Greenwich LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Greenwich LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.
